AstraZeneca Builds Another Respiratory Extension With Takeda Deal
This article was originally published in Scrip
Executive Summary
AstraZeneca is to pay $575m to acquire full rights to Takeda's Daxas (roflumilast), along with other respiratory assets. The move is the latest in a series of bolt-on acquisitions by the UK firm to bulk up its position in respiratory, one of its core therapeutic franchises along with oncology and cardiovascular/metabolic.
You may also be interested in...
AZ Clears Out Three Respiratory Drugs With Sale To Covis
The drug giant's strategy of divesting old assets continues apace with the $350m sale of the ciclesonide-based drugs Alvesco, Omnaris and Zetonna to the Swiss specialty pharma group.
Takeda Poised To Move Into Pharma Top 10 With Shire Combination
Takeda is clearly keen on Shire's rare disease therapies, but the future of the ophthalmology business, and notably the dry eye drug Xiidra, is less certain. The shutters may close on Shire's headquarters in Ireland as well.
Takeda Turnaround In Full Flow As New Products Deliver On Promise
Takeda Pharmaceutical Co. Ltd. has closed out its "turnaround year" on target, meeting guidance for fiscal 2015. The company has been undergoing a reorganization to pull it through intense generic competition and CEO Christophe Weber took the year-end opportunity to outline how the strategy was playing out for Japanese pharma.